The world's leading insulin manufacturer faces critical decisions as weight-loss drug demand strains production capacity. Market forces threaten the company's ability to serve all patients effectively ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

By Amina Niasse (Reuters) -Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its ...

This fast growth has created some high expectations for Hims & Hers stock. It now has a price-to-earnings ratio (P/E) of 79, ...

The team at Omada Health took a victory lap Friday after the company's successful Nasdaq debut, according to company President Wei-Li Shao. | The team at Omada Health took a victory lap Friday after ...

Among dozens of new laws signed this week by Gov. Jared Polis are consumer-friendly rules making it easier to cancel services online and a measure increasing access to weight-loss drugs.

He spotted the opportunity to invest in weight-loss drugs in 2023 before they exploded in 2024, and was an early AI mover, which he spied as a game changer in late 2022, early 2023. It's all about ...